HEMOSTASIS AND THROMBOSIS: Edited by Paul F. BrayThrombosis in myeloproliferative neoplasms: update in pathophysiologyReeves, Brandi N.a; Moliterno, Alison R.bAuthor Information aHematology Division, Department of Medicine, Blood Research Center, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina bHematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Correspondence to Alison R. Moliterno, MD, Hematology Division, Department of Medicine, Johns Hopkins University School of Medicine, Traylor 912, 720 Rutland Avenue, Baltimore, MD 21205, USA. Tel: +410 614 6360; fax: +410 614 0854; e-mail: [email protected] Current Opinion in Hematology: September 2021 - Volume 28 - Issue 5 - p 285-291 doi: 10.1097/MOH.0000000000000664 Buy Metrics Abstract Purpose of review This review summarizes high-impact research in myeloproliferative neoplasms (MPN) from the last 18 months, with a particular focus on basic science findings. Recent findings A pseudo-hypoxia state with stabilization of hypoxia-inducible factor (HIFα exists that is central to cell growth, cell renewal, inflammation, and thrombotic potential in MPN hematopoietic cells. Summary HIFα and inflammatory pathways are new therapeutic targets in MPN, with the potential to ameliorate thrombotic risk and perhaps eradicate mutant progenitor cells. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.